Champions Oncology, Inc.CSBRNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank74
3Y CAGR+76.8%
5Y CAGR-5.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+76.8%/yr
Quarterly compound
5Y CAGR
-5.8%/yr
Recent acceleration
Percentile
P74
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q1 2026 | 13.46% |
| Q4 2025 | 22.25% |
| Q3 2025 | -8.42% |
| Q2 2025 | 16.68% |
| Q1 2025 | 17.43% |
| Q4 2024 | -13.73% |
| Q3 2024 | -17.21% |
| Q2 2024 | -0.50% |
| Q1 2024 | 3.78% |
| Q4 2023 | -5.20% |
| Q3 2023 | 0.89% |
| Q2 2023 | 6.12% |
| Q1 2023 | 2.44% |
| Q4 2022 | 3.35% |
| Q3 2022 | -6.56% |
| Q2 2022 | 15.92% |
| Q1 2022 | 4.45% |
| Q4 2021 | -3.03% |
| Q3 2021 | 13.04% |
| Q2 2021 | -0.90% |
| Q1 2021 | 18.18% |
| Q4 2020 | 8.73% |
| Q3 2020 | -27.73% |
| Q2 2020 | 25.18% |
| Q1 2020 | 35.56% |
| Q4 2019 | -8.01% |
| Q3 2019 | 0.48% |
| Q2 2019 | 8.71% |
| Q1 2019 | 18.49% |
| Q4 2018 | 12.78% |
| Q3 2018 | -1.87% |
| Q2 2018 | -1.72% |
| Q1 2018 | 8.37% |
| Q4 2017 | -20.45% |
| Q3 2017 | -23.15% |
| Q2 2017 | 57.62% |
| Q1 2017 | -10.18% |
| Q4 2016 | -29.28% |
| Q3 2016 | 31.64% |
| Q2 2016 | 2.64% |